<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9887">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05688111</url>
  </required_header>
  <id_info>
    <org_study_id>HawlerMU5</org_study_id>
    <nct_id>NCT05688111</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid as an Intervention in Placenta Previa</brief_title>
  <official_title>Tranexamic Acid in Pregnant Women With Placentae Previa: A Double-blind, Multicenter Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hawler Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hawler Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antepartum hemorrhage (APH) due to placenta previa is an important cause of worldwide&#xD;
      perinatal mortality and maternal morbidity in pregnant women&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antepartum hemorrhage (APH) due to placenta previa is an important cause of worldwide&#xD;
      perinatal mortality and maternal morbidity in pregnant women. No medication is of specific&#xD;
      benefit to a patient with placenta previa. Tocolysis may be cautiously considered in some&#xD;
      circumstances in order to administer antenatal corticosteroids. A review article concluded&#xD;
      that there is no improvement in perinatal outcome with prolonged tocolytics, and tocolysis&#xD;
      beyond 48 hours is not clinically indicated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2023</start_date>
  <completion_date type="Anticipated">December 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization for both groups to the 2 groups will be done using Randomization Allocation Software program and whom will add the numbers on each syringe will be a pharmacist not involve in the study and will have the cods belong to the type of the intervention with him until the end of the research .&#xD;
Random Allocation Software(https://random-allocation-software.software.informer.com/2.0/)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Two similar size syringes will be prepared and labeled as A (experimental group) containing 1 g/10mL Tranexamic acid diluted with 20mL of 5% glucose water, and syringe B (placebo group) containing 30 mL of 5% glucose water.&#xD;
The 2 groups of syringes will be labeled with different numbers not known by the investigator or the patient</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To stope or decrease vaginal bleeding</measure>
    <time_frame>Up to time of delivery</time_frame>
    <description>Receiving Tranexamic acid decreases or stops vaginal bleeding in women with placenta previa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prolong pregnancy to 36 weeks</measure>
    <time_frame>Up to delivery of the fetus</time_frame>
    <description>Decreased vaginal bleeding may prolong pregnancy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Favorable perinatal outcome</measure>
    <time_frame>7 days post partum</time_frame>
    <description>Delivery of active newborn at or more than 36 weeks gestation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Interventional Drug in Placenta Previa</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose water group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 30 mL of 5% glucose water slowly intravenously immediately during the attack of the bleeding, twice daily for 48 hours. Accompanied with the usual expectant management care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid injection</intervention_name>
    <description>Active group will receive 1gm Tranexamic acid 12 hourly for 48 hours</description>
    <arm_group_label>Tranexamic acid group</arm_group_label>
    <other_name>Trenaxa; Macleods Pharmaceuticals Pvt.Ltd., Mumbai, India</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose water 5%</intervention_name>
    <description>Placebo group 30ml will be received 12 hourly for 48 hours</description>
    <arm_group_label>Glucose water group</arm_group_label>
    <other_name>Glucose B.Braun</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant at 24 weeks gestation and more&#xD;
&#xD;
          -  Vaginal bleeding due to placenta previa&#xD;
&#xD;
          -  Stable hemodynamically&#xD;
&#xD;
          -  Accept to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to tranexamic acid&#xD;
&#xD;
          -  Acquired defective color vision&#xD;
&#xD;
          -  History of venous thromboembolism&#xD;
&#xD;
          -  Pre-existing medical conditions (diabetes mellitus, hypertension, renal disease)&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Refused to participate in the trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SHAHLA K ALALAF, prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hawler Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ariana Jawad, professor</last_name>
    <role>Study Director</role>
    <affiliation>Kurdistan Higher Counsel of Medical Specialties</affiliation>
  </overall_official>
  <overall_official>
    <last_name>khalida Amin, Ass. Prof</last_name>
    <role>Study Chair</role>
    <affiliation>karkuk Medical college</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SHAHLA ALALAF, prof.</last_name>
    <phone>07504480711</phone>
    <phone_ext>00964</phone_ext>
    <email>shahla_alaf@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abu bakir Majeed, PhD</last_name>
    <phone>07504494656</phone>
    <phone_ext>00964</phone_ext>
    <email>abubakir.majeed@hmu.edu.krd</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ariana kh. Jawad</name>
      <address>
        <city>Erbil</city>
        <state>Kurdistan Region</state>
        <zip>44001</zip>
        <country>Iraq</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SHAHLA k. ALALAF</last_name>
      <phone>07504480711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kurdistan Board for Medical speciality</name>
      <address>
        <city>Erbil</city>
        <state>Kurdistan Region</state>
        <zip>44001</zip>
        <country>Iraq</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>07504480711</phone>
    </contact>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 8, 2023</study_first_submitted>
  <study_first_submitted_qc>January 8, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>January 19, 2023</last_update_submitted>
  <last_update_submitted_qc>January 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hawler Medical University</investigator_affiliation>
    <investigator_full_name>SHAHLA KAREEM ALALAF</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Placenta previa</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>intervention</keyword>
  <keyword>Double blind</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Previa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

